As U.S. markets navigate a period of uncertainty with the Federal Reserve maintaining interest rates and investors closely watching major tech earnings, attention turns to identifying promising growth opportunities. In such a climate, companies with high insider ownership can be appealing, as they often signal confidence from those most familiar with the business's potential.
Name | Insider Ownership | Earnings Growth |
Atour Lifestyle Holdings (NasdaqGS:ATAT) | 26% | 25.2% |
Super Micro Computer (NasdaqGS:SMCI) | 14.4% | 24.3% |
On Holding (NYSE:ONON) | 19.1% | 29.7% |
Kingstone Companies (NasdaqCM:KINS) | 20.8% | 24.9% |
Clene (NasdaqCM:CLNN) | 21.6% | 59.1% |
BBB Foods (NYSE:TBBB) | 22.9% | 40.4% |
Credit Acceptance (NasdaqGS:CACC) | 14.1% | 48% |
Smith Micro Software (NasdaqCM:SMSI) | 23.9% | 85.4% |
Neonode (NasdaqCM:NEON) | 22.6% | 110.9% |
CarGurus (NasdaqGS:CARG) | 16.6% | 42.3% |
Click here to see the full list of 204 stocks from our Fast Growing US Companies With High Insider Ownership screener.
Let's uncover some gems from our specialized screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Alphatec Holdings, Inc. is a medical technology company specializing in the design, development, and advancement of technologies for the surgical treatment of spinal disorders globally, with a market cap of approximately $1.62 billion.
Operations: The company's revenue is primarily derived from its Medical Products segment, which generated $572.74 million.
Insider Ownership: 11.9%
Revenue Growth Forecast: 14.9% p.a.
Alphatec Holdings is poised for growth, with insider ownership aligning interests with shareholders. The company expects significant revenue growth of approximately 20% in 2025, reaching US$732 million. Despite a volatile share price and current losses, Alphatec is forecast to become profitable within three years and shows strong earnings potential with an expected annual profit growth of 53.6%. Trading at a substantial discount to its estimated fair value also suggests good relative value compared to peers.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Clover Health Investments, Corp. offers Medicare Advantage plans in the United States and has a market cap of approximately $2.30 billion.
Operations: Clover Health Investments generates revenue through its provision of Medicare Advantage plans in the United States.
Insider Ownership: 21.6%
Revenue Growth Forecast: 10.4% p.a.
Clover Health Investments is positioned for potential growth, with insider ownership aligning interests. The company reported a reduced net loss of US$9.16 million for Q3 2024, down from US$41.47 million the previous year, indicating improving financials. Revenue is projected to grow at 10.4% annually, surpassing the broader US market's growth rate of 9%. Trading significantly below its estimated fair value suggests attractive valuation prospects despite current losses and no recent insider trading activity.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Youdao, Inc. is an internet technology company offering online services in content, community, communication, and commerce in China with a market cap of approximately $903.56 million.
Operations: The company's revenue segments include CN¥2.91 billion from Learning Services, CN¥1.97 billion from Online Marketing Services, and CN¥885.63 million from Smart Devices.
Insider Ownership: 20.3%
Revenue Growth Forecast: 11.8% p.a.
Youdao's earnings are forecast to grow significantly at 98.6% annually, outpacing the US market, though revenue growth of 11.8% lags behind high-growth benchmarks. The company recently became profitable, reporting a net income of CNY 86.25 million for Q3 2024 compared to a loss last year, indicating improving financial health despite large one-off items affecting results. There has been no substantial insider trading activity recently and interest payments remain poorly covered by earnings.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include NasdaqGS:ATEC NasdaqGS:CLOV and NYSE:DAO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。